

What is claimed is:

1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding TGF- β 2, wherein said
5 compound comprises at least a portion of a sequence selected from the group consisting of SEQ ID NO:53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 66 or 69, and wherein said compound modulates the expression of TGF- β 2.
- 10 2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified
15 internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage of the antisense oligonucleotide is a
phosphorothioate linkage.
20
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar
25 moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
30
8. The compound of claim 7 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.

9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. A composition comprising the compound of claim 1
5 and a pharmaceutically acceptable carrier or diluent.

11. The composition of claim 10 further comprising a colloidal dispersion system.

10 12. The composition of claim 10 wherein the compound is an antisense oligonucleotide.

13. A method of inhibiting the expression of TGF- β 2 in cells or tissues comprising contacting said cells or tissues
15 with the compound of claim 1 so that expression of TGF- β 2 is inhibited.

14. A method of treating an animal having a disease or condition associated with TGF- β 2 comprising administering to
20 said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of TGF- β 2 is inhibited.

15. The method of claim 14 wherein said disease or
25 condition is inflammation.

16. The method of claim 14 wherein said disease or condition is fibrosis or a fibrotic disease or condition.

30 17. The method of claim 16, wherein said fibrotic disease or condition is fibrotic scarring, peritoneal adhesions, lung fibrosis or conjunctival scarring.